Moderna Maintains Full-Year Revenue Growth Outlook Following Fourth-Quarter Beat

robot
Abstract generation in progress

PREMIUM

Moderna Maintains Full-Year Revenue Growth Outlook Following Fourth-Quarter Beat

MT Newswires

Sat, February 14, 2026 at 12:26 AM GMT+9 2 min read

In this article:

MRNA

+7.28%

Moderna (MRNA) reiterated its full-year revenue growth outlook on Friday, while the drugmaker report

PREMIUM

Upgrade to read this MT Newswires article and get so much more.

A Silver or Gold subscription plan is required to access premium news articles.

Upgrade

Already have a subscription? Sign in

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin